Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

Archive ouverte

Lepage, C. | Phelip, M. | Cany, L. | Maillard, E. | Lievre, A. | Chatellier, T. | Faroux, R. | Duchmann, J-C. | Ben Abdelghani, M. | Breysacher, G. | Geoffroy, P. | Pere-Verge, D. | Pelaquier, A. | Pillon, D. | Ezenfis, J. | Rinaldi, Y. | Darut-Jouve, A. | Duluc, M. | Adenis, Antoine | Bouché, O.

Edité par CCSD -

International audience. Background: PRODIGE 13 is a cooperative prospective multicentre controlled phase III trial evaluating by double randomisation the impact of intensive radiological monitoring versus a standard one and CEA monitoring versus no monitoring in Stage II or III colorectal cancer. This abstract describes patient's baseline characteristics.Methods: Recommendations for colorectal cancer, according to various scientific societies have been based on heterogeneous clinical trials, and indeed mainly on expert opinions. Differences still exist particularly concerning the imaging techniques used. The CEA dosage is also poorly evaluated. Despite their limits, recent trials suggest that survival is increased thanks to clinical monitoring combined with hepatic and pulmonary imaging and possibly CEA assay. PRODIGE 13 is a large randomised trial of monitoring strategy and will evaluate the strategies to...

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion